EP 050 Industry Insights - AI in Longevity Research
Vorschaubild von YouTube. Abspielen lädt den YouTube-Player.
Verlauf & EmpfehlungenAus
Zuletzt angesehene Inhalte in diesem Browser behalten. Dein Verlauf bleibt auf diesem Gerät und wird nicht an Harbor gesendet. Abgespielte Videos können auch passende Videoempfehlungen sortieren.
Merkliste & Verlauf öffnen →Über dieses Video
Beschreibung des Creators · Originalsprache
EPISODE 050: "AI in Longevity Research"
ARTIFICIAL INTELLIGENCE | Longevity Science | Anti-Aging Medicine | Pharmaceutical Manufacturing | Healthspan Extension
Discover how artificial intelligence is revolutionizing longevity research and creating unprecedented demand for pharmaceutical manufacturing capacity. This episode explores the convergence of AI and aging science—from drug discovery that's 70% successful (compared to single-digit success rates in traditional methods) to the first FDA-approved dog longevity trials paving the way for human therapies. Learn why extending healthy human lifespan by just one year could add $38 trillion to the global economy.
KEY TOPICS COVERED:
The Science of Aging
The 12 hallmarks of aging: cellular senescence, mitochondrial dysfunction, telomere shortening
Lifespan vs healthspan: adding life to years, not just years to life
Biological age vs chronological age measured with AI-powered aging clocks
Polypharmacology: targeting multiple aging pathways simultaneously
Loyal's STAY study with 1,300+ dogs testing longevity drugs
IGF-1 targeting for metabolic aging in large breeds
AI & Machine Learning Breakthroughs
Multi-omics analysis integrating genomics, proteomics, microbiome, and metabolome data
Generative AI designing novel molecules in 46 days (Insilico Medicine)
70% success rate in AI-identified anti-aging compounds (Scripps Research, May 2025)
In-silico modeling and digital twins for virtual clinical trials
Drug repurposing: discovering hidden longevity benefits in existing medications
Current Clinical Breakthroughs
GLP-1 revolution: Ozempic, Wegovy, Mounjaro showing unexpected longevity benefits
Metformin and rapamycin in clinical trials as anti-aging drugs
Cellular reprogramming: reversing biological age at the cellular level
NAD+ boosters and senolytic drugs clearing zombie cells
FDA approval pathway for dog longevity drugs (LOY-002)
INS018_055: AI-designed drug showing activity against six aging mechanisms
Manufacturing Revolution & Scalability
Cloud-based Manufacturing Execution Systems (MES) for unprecedented demand
Lessons from Ozempic shortage and the coming longevity surge
Real-time orchestration for complex biologics, cell therapies, gene therapies
AI-powered production optimization and predictive bottleneck prevention
Digital twin manufacturing simulations
Connected manufacturing networks across global facilities
Economic & Societal Impact
Projected longevity drug market: $75-140 billion by 2030
Novo Nordisk's $16.5B Catalent acquisition; Eli Lilly's $50B+ capacity investment
"Longevity as a Service" subscription models
Restructuring society: multiple careers, extended productivity
Democratizing access to longevity treatments globally
Future Predictions
First wave of AI-designed longevity drugs (2025-2027)
100x demand increase for longevity pharmaceuticals
Cellular reprogramming clinics for biological age reversal
Maximum human healthspan potentially reaching 120+ years
3D-printed organs and on-demand replacement parts
Perfect for:
Pharmaceutical manufacturing professionals
Biotechnology researchers and scientists
Contract Manufacturing Organization (CMO) executives
Healthcare innovation and longevity enthusiasts
Quality assurance and regulatory specialists
Manufacturing operations leaders
Featured Companies & Technologies: Loyal (STAY Study) | Insilico Medicine | Novo Nordisk | Eli Lilly | Catalent | IIT-Delhi AgeXtend | Apprentice.io Tempo MES
Host: Frank Maggiore
Series: Apprentice.io Industry Insights Podcast
#longevity #AIinMedicine #AntiAging #Pharmaceutical #Biotechnology #Manufacturing #Healthspan #DrugDiscovery #PrecisionMedicine #CloudMES #BiologicalAge #GLP1 #CellularReprogramming #Bioreactors #PharmaceuticalManufacturing #MES #HealthTech #AgingResearch #BioManufacturing #DigitalTransformation
ENGAGE WITH US:
Like, comment with your thoughts on longevity medicine
Subscribe for weekly science-based pharmaceutical insights
Share with colleagues in pharma and biotech
Learn more: apprentice.io
Disclaimer: The content in this video podcast is for informational purposes only. The views and opinions expressed are those of the speakers and do not necessarily reflect the official policy or position of Apprentice.io or any other agency, organization, employer or company. This podcast does not constitute medical, financial, regulatory, or legal advice. Viewers should consult with appropriate professionals for specific advice. Apprentice.io makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability of the information contained in this video. Any reliance you place on such information is strictly at your own risk.
Related Topics: drug repurposing, metformin longevity, rapamycin, senolytics, biopharmaceutical manufacturing, fermentation technology, CMO partnerships, GMP compliance, bioprocess engineering
Apprentice · 36 min · Quelle veröffentlicht: 2025-09-19
Zu Harbor hinzugefügt: 22.10.2026
Original auf YouTube ↗Automatisch eingeordnete Quelle. Creator-Aussagen sind keine unabhängige Evidenzprüfung und keine persönliche medizinische Beratung.